FDA approves first deuterated drug
AUSTEDO® (deutetrabenazine) tablets: Tardive Dyskinesia and Huntington's Chorea Treatment
Teva's Austedo is first 'heavy hydrogen' drug to win US FDA approval
Teva's Austedo Fails a Pair of Tourette Syndrome Trials – PharmaLive
Deuterated tetrabenazine (Austedo™) receives FDA Approval for Teva.
Rx Item-Austedo Tab 9Mg 60 By Teva Pharma
Austedo | Medic
Tardive Dyskinesia Treatment, Causes, & Symptoms
Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive Dyskinesia
China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults | Business Wire
2020 Pharma Choice DTC/DTP Silver Winner Intouch Group and Teva | PM360
Ajovy and Austedo: Teva Pharmaceutical's Growth Strategy
2020 Pharma Choice DTC/DTP Silver Winner Intouch Group and Teva | PM360
NDC 68546-171 Austedo Deutetrabenazine
AUSTEDO- deutetrabenazine tablet, coated AUSTEDO- deutetrabenazine kit
Teva's Austedo (deutetrabenazine) Receives the NMPA's Approval to Treat Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults
jabo - Teva Austedo Academy
Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease
Austedo - FDA prescribing information, side effects and uses
Teva settles patent dispute with Lupin over Austedo (NYSE:TEVA) | Seeking Alpha
Starting Patients | AUSTEDO® (deutetrabenazine) tablets
